Pharmacological profile of novel psychoactive benzofurans

British Journal of Pharmacology

Volumn 172, Issue 13, 2015, Pages 3412-3425

  Rickli, Anna ^a   Kopf, Simone ^a   Hoener, Marius C ^b   Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDROBENZOFURAN 5 YL) N METHYLPROPAN 2 AMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 (2 AMINOPROPYL)BENZOFURAN; 5 (2 AMINOPROPYL) 2,3 DIHYDROBENZOFURAN; 5 (2 AMINOPROPYL)BENZOFURAN; 5 (2 ETHYLAMINOPROPYL)BENZOFURAN; 6 (2 AMINOPROPYL) 2,3 DIHYDROBENZOFURAN; 6 (2 AMINOPROPYL)BENZOFURAN; 7 (2 AMINOPROPYL)BENZOFURAN; 8 BROMO 2,3,6,7 BENZO DIHYDRODIFURAN ETHYLAMINE; BENZOFURAN DERIVATIVE; DOPAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; NORADRENALIN; NORADRENALIN TRANSPORTER; RECEPTOR; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; TRACE AMINE ASSOCIATED RECEPTOR 1; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR; PSYCHOTROPIC AGENT; SEROTONIN RECEPTOR;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HEK293 CELL LINE; IC50; IN VITRO STUDY; NORADRENALIN RELEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; SEROTONIN RELEASE; STRUCTURE ACTIVITY RELATION; CELL SURVIVAL; DRUG EFFECTS; HUMAN; METABOLISM;

BENZOFURANS; CELL SURVIVAL; DOPAMINE; HEK293 CELLS; HUMANS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PSYCHOTROPIC DRUGS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 84937432279     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13128     Document Type: Article

References (67)

1. 2C receptors. Br J Pharmacol 136: 510-519.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: transporters. Br J Pharmacol 170: 1706-1796.
4. Andreasen MF, Telving R, Birkler RI, Schumacher B, Johannsen M, (2009). A fatal poisoning involving Bromo-Dragonfly. Forensic Sci Int 183: 91-96.
5. Archer JR, Dargan PI, Lee HM, Hudson S, Wood DM, (2014). Trend analysis of anonymised pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances. Clin Toxicol (Phila) 52: 160-165.
6. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
7. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J, (2009). Drug-induced fibrotic valvular heart disease. Lancet 374: 577-585.
8. Blessing WW, Seaman B, Pedersen NP, Ootsuka Y, (2003). Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats. J Neurosci 23: 6385-6391.
9. Bluelight (2013a). The Main 5-APDB Thread. Available at: http://www.bluelight.org/vb/threads/672585-The-Main-5-APDB-Thread (accessed 20/12/2014).
10. Bluelight (2013b). The Main 6-APDB Thread. Available at: http://www.bluelight.org/vb/threads/661435-The-Main-6-APDB-Thread (accessed 20/12/2014).
11. 2A/2C receptor agonists. J Med Chem 44: 1003-1010.
12. Chan WL, Wood DM, Hudson S, Dargan PI, (2013). Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. J Med Toxicol 9: 278-281.
13. Cole JC, Sumnall HR, (2003). The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27: 199-217.
14. Crouch SP, Kozlowski R, Slater KJ, Fletcher J, (1993). The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 160: 81-88.
15. 2-dependent vasoconstriction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 48: 57-63.
16. Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, et al. (2011). Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J Neurosci 31: 16928-16940.
17. Docherty JR, Green AR, (2010). The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol 160: 1029-1044.
18. Drugs-Forum (2013). 5-EAPB (1-(benzofuran-5-yl)-N-ethylpropan-2-amine). Available at: https://www.drugs-forum.com/forum/showthread.php?t=217991 (accessed 20/12/2014).
19. Elliott S, Evans J, (2014). A 3-year review of new psychoactive substances in casework. Forensic Sci Int 243C: 55-60.
20. EMCDDA (2014). European Drug Report 2014. European Monitoring Center for Drugs and Drug Addiction (EMCDDA). Available at: www.emcdda.europa.eu (accessed 20/12/2014).
21. Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB, (2014). Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology (Berl) 231: 875-888.
22. Felser A, Lindinger PW, Schnell D, Kratschmar DV, Odermatt A, Mies S, et al. (2014). Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure. Toxicology 324: 136-146.
23. Greene SL, (2013). Benzofurans and benzodifurans. In:, Dargan PI, Wood DM, (eds). Novel Psychoactive Substances. Elsevier: Amsterdam, pp. 283-392.
24. Han DD, Gu HH, (2006). Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6: 6.
25. 2A/2C agonists. ACS Chem Neurosci 5: 243-249.
26. Hill SL, Thomas SH, (2011). Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 49: 705-719.
27. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, et al. (2011). The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ('ecstasy') in humans. Clin Pharmacol Ther 90: 246-255.
28. 2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340: 286-294.
29. Hysek CM, Schmid Y, Rickli A, Simmler LD, Grouzmann E, Liechti ME, (2012b). Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Swiss Med Forum 12 (S58): 110S.
30. Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, et al. (2012c). Duloxetine inhibits effects of MDMA ('ecstasy') in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE 7: e36476.
31. Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME, (2013). α-Adrenergic receptors contribute to the acute effects of MDMA in humans. J Clin Psychopharmacol 33: 658-666.
32. Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL, (2013). Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 700: 147-151.
33. Jebadurai J, Schifano F, Deluca P, (2013). Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl) benzofuran (benzofury/ 6-APB) and NRG-2 with review of available evidence-based literature. Hum Psychopharmacol 28: 356-364.
34. 1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33: 2303-2312.
35. King LA, (2014). New phenethylamines in Europe. Drug Test Anal 6: 808-818.
36. Lamb RJ, Griffiths RR, (1987). Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology (Berl) 91: 268-272.
37. Liechti ME, (2014a). Effects of MDMA on body temperature in humans. Temperature 1: 179-187.
38. Liechti ME, (2014b). Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling. Swiss Med Wkly 144: w14043.
39. 2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23: 396-404.
40. Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE, (1993). Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. J Med Chem 36: 3700-3706.
41. Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE, (1996). Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J Med Chem 39: 2953-2961.
42. Monte AP, Waldman SR, Marona-Lewicka D, Wainscott DB, Nelson DL, Sanders-Bush E, et al. (1997). Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem 40: 2997-3008.
43. 2C receptors. Naunyn Schmiedebergs Arch Pharmacol 359: 1-6.
44. Nichols DE, (1994). Medicinal chemistry and structure-activity relationships. In:, Cho AK, Segal DS, (eds). Amphetamine and Its Analogs: Psychopharmacology, Toxicology and Abuse. Academic Press: London, pp. 3-41.
45. Nichols DE, (2004). Hallucinogens. Pharmacol Ther 101: 131-181.
46. Nielsen VT, Hogberg LC, Behrens JK, (2010). Bromo-Dragonfly poisoning of 18-year-old male. Ugeskr Laeger 172: 1461-1462.
47. 2A receptor. J Med Chem 41: 5148-5149.
48. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
49. 1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A 108: 8485-8490.
50. Rickli A, Hoener MC, Liechti ME, (2015). Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 25: 365-376.
51. Roth BL, (2007). Drugs and valvular heart disease. N Engl J Med 356: 6-9.
52. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
53. Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. (2014). Acute effects of LSD in healthy subjects. Biol Psychiatry. doi: 10.1016/j.biopsych.2014.11.015
54. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH, (2000). Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther 293: 870-878.
55. Seetohul LN, Pounder DJ, (2013). Four fatalities involving 5-IT. J Anal Toxicol 37: 447-451.
56. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, et al. (2003). 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63: 1223-1229.
57. Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. (2013). Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168: 458-470.
58. Simmler LD, Rickli A, Hoener MC, Liechti ME, (2014a). Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79: 152-160.
59. Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME, (2014b). Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem Pharmacol 88: 237-244.
60. Stanczuk A, Morris N, Gardner EA, Kavanagh P, (2013). Identification of (2-aminopropyl)benzofuran (APB) phenyl ring positional isomers in internet purchased products. Drug Test Anal 5: 270-276.
61. Strano Rossi S, Odoardi S, Gregori A, Peluso G, Ripani L, Ortar G, et al. (2014). An analytical approach to the forensic identification of different classes of new psychoactive substances (NPSs) in seized materials. Rapid Commun Mass Spectrom 28: 1904-1916.
62. Tatsumi M, Groshan K, Blakely RD, Richelson E, (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249-258.
63. Thorlacius K, Borna C, Personne M, (2008). Bromo-dragon fly-life-threatening drug. Can cause tissue necrosis as demonstrated by the first described case. Lakartidningen 105: 1199-1200.
64. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D, (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-3902.
65. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL, (2005). Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313: 848-854.
66. Welter J, Kavanagh P, Meyer MR, Maurer HH, (2015). Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem 407: 1371-1388.
67. Wood DM, Looker JJ, Shaikh L, Button J, Puchnarewicz M, Davies S, et al. (2009). Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. J Med Toxicol 5: 226-229.